An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present)
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Therapeutic Patents"
DOI: 10.1080/13543776.2022.2132851
Abstract: ABSTRACT Introduction Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase. Aberrations in RET signaling due to mutations, gene fusions, or overexpression can lead to carcinomas. Six inhibitors have been approved for the treatment… read more here.
Keywords: kinase; ret inhibitors; ret; rearranged transfection ... See more keywords
Is There Any Mosaicism in REarranged During Transfection Variant in Hirschsprung Disease’s Patients?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pediatrics"
DOI: 10.3389/fped.2022.842820
Abstract: Background Hirschsprung disease (HSCR) is a heterogeneous genetic disease characterized by the absence of ganglion cells in the intestinal tract. The REarranged during Transfection (RET) is the most responsible gene for its pathogenesis. RET’s somatic… read more here.
Keywords: hscr; rearranged transfection; ret rs2435357; hirschsprung disease ... See more keywords